The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
Official Title: A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination With AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
Study ID: NCT04885998
Brief Summary: The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
University of Kentucky, Lexington, Kentucky, United States
Wake Forest Baptist Comprehensive Cancer Research Center, Winston-Salem, North Carolina, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Medizinische Universitaet Innsbruck, Innsbruck, , Austria
Universitaetsklinikum Allgemeines Krankenhaus Wien, Wien, , Austria
Universitair Ziekenhuis Antwerpen, Edegem, , Belgium
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, , Belgium
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
National University Hospital, Singapore, , Singapore
National Cancer Centre Singapore, Singapore, , Singapore
Chung Shan Medical University Hospital, Taichung, , Taiwan
Taipei Veterans General Hospital, Taipei, , Taiwan
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR